Sernova Corp - SEOVF stock
OTC Symbol: SEOVF | OTC Tier: OTCQB | Related ticker symbols: TSX: SVA
About[edit]
Sernova Corp. is a clinical-stage regenerative medicine therapeutics company based in London, Canada, specializing in the development and commercialization of regenerative medicine therapeutics, particularly its proprietary Cell Pouch and associated technologies, which facilitate the transplantation and engraftment of therapeutic cells in a vascularized tissue environment, enabling long-term treatment of serious chronic diseases like diabetes, hemophilia, and thyroid disease. The company also has research collaborations with AgeX Therapeutics, Inc., the University of Miami, and AstraZeneca PLC to explore immune-protected therapeutic cells and potential therapeutic cell applications.[1]
History[edit]
Sernova Corp. was founded in 1998 in Canada. The company's origin lies in its establishment as a regenerative medicine therapeutics company, focusing on the development and commercialization of innovative treatments for chronic diseases.[2]
Sernova Corp. has dedicated its efforts to advancing the field of regenerative medicine, with a specific focus on its proprietary technology known as the Cell Pouch. This medical device is designed to create a vascularized tissue environment, providing a platform for the transplantation and engraftment of therapeutic cells. Once implanted, these therapeutic cells release proteins and/or hormones to address the underlying causes of various serious chronic diseases, such as diabetes, hemophilia, and thyroid disease.[3]
Over the years, Sernova has conducted clinical-stage trials and research collaborations to explore the potential of its Cell Pouch technology and other regenerative medicine therapeutics. Notably, the company has established research collaborations with AgeX Therapeutics, Inc., the University of Miami, and AstraZeneca PLC to enhance its understanding of immune-protected therapeutic cells and explore novel therapeutic cell applications.[3]
Products[edit]
Cell Pouch[edit]
In Q1 2025 Sernova Biotherapeutics submitted an Investigational New Drug (IND) application to the U.S. FDA to evaluate its Cell Pouch implanted with thyroid cells in patients undergoing total thyroidectomy for nodular thyroid disease. The study aims to assess whether the Cell Pouch can restore natural thyroid function in post-operative hypothyroidism patients, potentially eliminating the need for lifelong hormone replacement therapy.[4] The company also has a non-binding letter of intent with HealthGena and GOLDTRACK Ventures to explore opportunities for product development and commercialization in Saudi Arabia under ‘Project REEM Ventures.[5]
Funding[edit]
A non-brokered, private placement was completed in September, 2024. The placement produced proceeds of $5.2 million.[6]
- ↑ Yahoo Finance. SEOVF Stock Profile. Retrieved on 11/2/2023.
- ↑ Money.com. SEOVF Profile. Retrieved on 8/16/2023.
- ↑ 3.0 3.1 sernova.com. Company. Retrieved on 11/2/2023.
- ↑ GlobeNewswire. Sernova Biotherapeutics Submits IND Application for its Cell Pouch Bio-Hybrid Organ with Autograft Thyroid Cells in Patients with Hypothyroidism. February 3, 2025.
- ↑ Yahoo. Sernova Update on Strategic Initiatives. December 2, 2024.
- ↑ TheNewswire. Sernova Closes $5.2 Million Over-Subscribed Non-Brokered, Private Placement. September 4, 2024. Archive link.
